Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Abstract Background Treatment of systemic onset juvenile idiopathic arthritis JIA (sJIA), although dramatically improved, remains a challenge. Experience from clinical practice will be presented using data from the German Biologics register (BiKeR) for evaluation of efficacy and safety of treatment...

Full description

Bibliographic Details
Main Authors: Gerd Horneff, Anna Carina Schulz, Jens Klotsche, Anton Hospach, Kirsten Minden, Ivan Foeldvari, Ralf Trauzeddel, Gerd Ganser, Frank Weller-Heinemann, Johannes Perter Haas
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Arthritis Research & Therapy
Subjects:
Systemic onset juvenile idiopathic arthritis
Still’s disease
Anakinra
Canakinumab
Etanercept
Tocilizumab
Online Access:http://link.springer.com/article/10.1186/s13075-017-1462-2

Internet

http://link.springer.com/article/10.1186/s13075-017-1462-2

Similar Items